Table 1 Baseline characteristics of the 6 individual cohorts (and their study fractions) and their meta-cohort

From: Activated GDF11/8 subforms predict cardiovascular events and mortality in humans

Covariate

Measure

HUNT3 secondary

ARIC secondary

ARIC primary elderly

BASEL VIII secondary

BASEL VIII primary

EXSCEL Placebo baseline

Meta-cohort with 4-year outcomes

Population

Purpose/duration

Studies or study fractions with 4 year outcomes included in meta-cohort

All 4 year studies merged dataset

Study fraction and Morbidity

20% of total secondary population

80% of total visit 5 secondary population

100% of visit 5 primary population aged >65

100% secondary w/CAD symptoms

100% primary w/CAD symptoms

100% of placebo; type 2 diabetes

Multi morbidity

Sample size

139

784

4078

2410

1675

2523

11,609

Composite CV Event

Event (%)

37

(26.6%)

Death=14

CHF = 10

MI = 10

Stroke = 3

390

(49.7%)

Death=72

CHF = 207

MI = 80,

Stroke = 31

817

(20.0%)

Death=350

CHF = 253

MI = 109

Stroke=105

627

(26.0%)

Death=236

CHF = 77,

MI = 218

Stroke = 96

181

(10.8%)

Death=124

CHF = 18

MI = 11

Stroke = 28

488

(19.3%)

Death=176

CHF = 57,

MI = 173

Stroke = 82

2540

(21.9%)

Death=972

CHF = 622

MI = 601

Stroke = 345

No event (%)

102 (73.4%)

394 (50.3%)

3261 (80.0%)

1783 (74.0%)

1494 (89.2%)

2035 (80.7%)

9069 (78.1%)

Follow-up time (days)

Mean events

(SD)

Range

638

(432)

4−1675

910

(616)

7 – 2232

1136

(580)

4-2375

776

(647)

1 - 2958

863

(679)

7 - 2822

725

(477)

1-1950

907

(614)

1 - 2958

Mean no events

(SD)

Range

1721

(175)

1407 - 2035

2019

(257)

238 – 2389

2042

(235)

134-2404

1421

(669)

361 - 3024

1392

(681)

267 - 3054

1423

(346)

1-2112

1674

(558)

1 - 3054

Age (years)

Mean

(SD)

Range

69.5

(10.8)

44−92

77.2

(5.3)

67−90

75.3

(5.1)

66-90

68.1

(10.6)

34 - 93

65.9

(11.8)

26 - 95

62.8

(9.4)

29 – 88

69.8

(10.1)

26 - 95

Sex

Male (%)

108 (77.7%)

498 (63.5%)

1581 (38.8%)

1891 (78.5%)

855 (51.0%)

1520 (60.2%)

6453 (55.6%)

Female (%)

31 (22.3%)

286 (36.5%)

2497 (61.2%)

519 (21.5%)

820 (49.0%)

1003 (39.8%)

5156 (44.4%)

Race

White (%)

n/a

652 (83.2%)

3322 (81.5%)

n/a

n/a

2032 (80.5%)

10,230 (88.2%)

Black (%)

n/a

132 (16.8%)

756 (18.5%)

n/a

n/a

44 (1.7%)

932 (8%)

Asian (%)

n/a

0

0

n/a

n/a

176 (7.0%)

176 (1.5%)

Latine (%)

n/a

0

0

n/a

n/a

260 (10.3%)

260 (2.2%)

Other (%)

n/a

0

0

n/a

n/a

11 (0.4%)

11 (0.10%)

  1. CV cardiovascular, CAD coronary artery disease, CHF congestive heart failure, MI myocardial infarction, n/a not applicable, HUNT3 Trøndelag Health Study, ARIC Atherosclerosis Risk in Communities, BASEL VIII Biochemical and Electrocardiographic Signatures in the Detection of Exercise-induced Myocardial Ischemia, EXSCEL Exenatide Study of Cardiovascular Event Lowering.